Back to News
Market Impact: 0.25
Alnylam Presents New Data Validating AMVUTTRA In ATTR; Provides Updates On Zilebesiran
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsTechnology & Innovation
Alnylam reported new ESC 2026 data reinforcing AMVUTTRA’s therapeutic ability in treating transthyretin amyloidosis (ATTR). The update is supportive of efficacy and strengthens the clinical narrative for the RNAi asset, though no specific efficacy or financial metrics were provided in the article.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
ALNY0.35
More News
- CoreWeave credit default swaps hit distress levels as investors sour on AI debt
- Penske Automotive agrees to be taken private by Penske, Mitsui
- Supermicro promised a new CFO in December 2024. A $2.5 billion smuggling case and a co-founder’s arrest later, it has one
- Blackstone President Jon Gray Bets Big on AI Boom
- What's behind the sell-off in AI neocloud stocks like CoreWeave and Nebius
- Giant Taiwanese chipmaker TSMC confirms it’s in talks with Elon Musk to join ‘Terafab’ complex in Texas: ‘The AI market continues to be very strong’